The Company’s proprietary diffusion-enhancement technology covers a new class of pharmaceuticals in the U.S. and all major worldwide markets.

Highlights of the Company’s Patent Estate:

• Intellectual property coverage in the U.S. and all major worldwide markets for the Company’s lead drug candidate, TSC, its New Chemical Entity (NCE) pipeline, compositions of matter, synthesis, uses and formulations
• Multiple issued U.S. and foreign patents, as well as registered U.S. service and trademarks
• Numerous pending U.S. applications and corresponding foreign applications

Protection of our intellectual property, which the Company controls without any obligations to third parties, is an important part of our strategy as evidenced by the more than 100 patent applications the Company has filed.